Skip to main content

Idera Pharmaceuticals, Inc. (IDRA)

NASDAQ: IDRA · Delayed Price · USD
+0.028 (3.16%)
After-hours:Oct 25, 2021 7:59 PM EDT
-0.009 (-1.00%)
At close: Oct 25, 4:00 PM

Company Description

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States.

It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer.

The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals Logo
CountryUnited States
IPO DateJan 24, 1996
SectorHealth Care
CEOVincent Milano

Contact Details

505 Eagleview Blvd Ste 212
Exton, Pennsylvania 19341-1199
United States
Phone484 348 1600

Stock Details

Ticker SymbolIDRA
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0000861838
CUSIP Number44860M108
ISIN NumberUS45168K4058
Employer ID04-3072298

Key Executives

Vincent J. MilanoPresident, Chief Executive Officer and Director
John J. KirbySenior Vice President and Chief Financial Officer
Bryant David LimSenior Vice President, General Counsel and Corporate Secretary
Robert Clayton FletcherConsultant
Daniel B. SolandSenior Vice President and Chief Operating Officer
Jill ConwellSenior Vice President of Investor Relations and Corporate Communications
Elizabeth EberhardtSenior Vice President of Product Leadership
Dr. Shah Rahimian M.D., Ph.D.Medical Director and Global Clinical Lead for Oncology
Dr. Joanna C. Horobin Ch.B, M.B.Advisor
Dr. Sudhir AgrawalScientific Advisor